Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Reporting Date: October 22, 2025 (Event Date); October 24, 2025 (Filing Date)
Context: The filing discloses the establishment of a new scientific advisory board and the release of an updated corporate presentation. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes
- Scientific Advisory Board: Established on October 22, 2025, to further develop the RedTail platform and advance the clinical development of CLD-401.
- Corporate Presentation: An updated presentation regarding the Company was made available on its website on October 24, 2025.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize the new scientific advisory board to advance CLD-401 into the clinic and develop the RedTail platform.
Regulatory Note: The information furnished under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events) is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the content of the updated corporate presentation (Exhibit 99.1) for specific strategic updates.
- Examine the press release (Exhibit 99.2) for details on the composition and expertise of the new scientific advisory board.
- Verify the clinical timeline for CLD-401 as outlined in the new presentation materials.
- Confirm the company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K does not contain financial statements.